Blood-based Migration Signature Biomarker Panel Discriminates Early Stage New Onset Diabetes related Pancreatic Ductal Adenocarcinoma from Type 2 Diabetes

Authors

Seetharaman Balasenthil
Suyu Liu
Jianliang Dai
William R Bamlet
Gloria Petersen
Suresh T Chari
Anirban Maitra
Nanyue Chen
Subrata Sen
Ann McNeill Killary

Language

English

Publication Date

11-1-2023

Journal

Clinica Chimica Acta

DOI

10.1016/j.cca.2023.117567

PMID

37774897

PMCID

PMC12626237

PubMedCentral® Posted Date

11-19-2025

PubMedCentral® Full Text Version

Author MSS

Abstract

Background and aims: While type 2 diabetes is a well-known risk factor for pancreatic ductal adenocarcinoma (PDAC), PDAC-induced new-onset diabetes (PDAC-NOD) is a manifestation of underlying PDAC. In this study, we sought to identify potential blood-based biomarkers for distinguishing PDAC-NOD from type 2 diabetes (T2DM) without PDAC.

Materials and methods: By ELISA analysis, a migration signature biomarker panel comprising tissue factor pathway inhibitor (TFPI), tenascin C (TNC-FNIII-C) and CA 19-9 was analyzed in plasma samples from 50 PDAC-NOD and 50 T2DM controls.

Results: Both TFPI (area under the curve (AUC) 0.71) and TNC-FNIII-C (AUC 0.69) outperformed CA 19-9 (AUC 0.60) in distinguishing all stages of PDAC-NOD from T2DM controls. The combined panel showed an AUC of 0.82 (95% CI = 0.73-0.90) (p = 0.002). In the PDAC-NOD early stage II samples, the three biomarkers had an AUC of 0.84 (95% CI = 0.73-0.93) vs CA 19-9, AUC = 0.60, (95% CI = 0.45-0.73), which also improved significance (p = 0.0123).

Conclusion: The migration signature panel adds significantly to CA 19-9 to discriminate PDAC-NOD from T2DM controls and warrants further validation for high-risk group stratification.

Keywords

Humans, Diabetes Mellitus, Type 2, Biomarkers, Tumor, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, CA-19-9 Antigen, Biomarkers, Blinded Validation, Diabetes, Early Detection, Pancreatic Cancer

Published Open-Access

yes

Recommended Citation

Balasenthil, Seetharaman; Liu, Suyu; Dai, Jianliang; et al., "Blood-based Migration Signature Biomarker Panel Discriminates Early Stage New Onset Diabetes related Pancreatic Ductal Adenocarcinoma from Type 2 Diabetes" (2023). Faculty, Staff and Student Publications. 6504.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/6504